Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report.

Ledinek AH; Jazbec SS; Drinovec I; Rot U

doi:10.1177/1352458509104593

Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report.

Affiliations

1. Department of Neurology, Medical Centre, Ljubljana, Slovenia.
Authors
Ledinek AH¹
(1 author)

Multiple Sclerosis (Houndmills, Basingstoke, England), 22 May 2009, 15(7):885-886
https://doi.org/10.1177/1352458509104593 PMID: 19465452

Abstract

A 23-year-old woman with multiple sclerosis developed respiratory symptoms 3 years after introduction of interferon beta-1b. The diagnosis of pulmonary arterial hypertension (PAH) was established. The patient partially responded to sildenafil and bosetan treatment. This is the first report of PAH, associated with interferon beta therapy. As shown in experimental models, interferon treatment can induce PAH by stimulation of thromboxane cascade and secretion of various inflammatory mediators.

Full text links

Read article at publisher's site: https://doi.org/10.1177/1352458509104593

Subscription required at ingentaconnect
http://openurl.ingenta.com/content?genre=article&issn=1352-4585&volume=15&issue=7&spage=885

Free to read at msj.sagepub.com
http://msj.sagepub.com/cgi/content/abstract/15/7/885

References

Articles referenced by this article (10)

Multiple sclerosis: side effects of interferon beta therapy and their management.
Walther EU, Hohlfeld R
Neurology, (8):1622-1627 1999
MED: 10563602
Vascular events associated with alpha interferon therapy.
Al-Zahrani H, Gupta V, Minden MD, Messner HA, Lipton JH
Leuk Lymphoma, (3):471-475 2003
MED: 12688317
Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies.
Anderson P, Hoglund M, Rodjer S
Am J Hematol, (1):54-58 2003
MED: 12701122
Pulmonary artery hypertension during interferon-alpha therapy for chronic myelogenous leukemia.
Fruehauf S, Steiger S, Topaly J, Ho AD
Ann Hematol, (5):308-310 2001
MED: 11446736
Acute right ventricular heart failure in a patient with renal cell carcinoma after interferon therapy.
Kramers C, de Mulder PH, Barth JD, Wagener DJ
Neth J Med, (1-2):65-68 1993
MED: 8446228
Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report.
Jochmann N, Kiecker F, Borges AC, Hofmann MA, Eddicks S, Sterry W, Baumann G, Trefzer U
Cardiovasc Ultrasound, 26 2005
MED: 16138923
Interferon-alpha elevates pulmonary blood pressure in sheep--the role of thromboxane cascade.
Hanaoka M, Kubo K, Hayano T, Koizumi T, Kobayashi T
Eur J Pharmacol, (2):145-151 1999
MED: 10323263
Inflammation in pulmonary arterial hypertension.
Dorfmuller P, Perros F, Balabanian K, Humbert M
Eur Respir J, (2):358-363 2003
MED: 12952274
Acute effects of interferon beta-1a on plasma cytokine levels in patients with MS.
Kumpfel T, Then Bergh F, Pollmacher T, Holsboer F, Trenkwalder C
Neurology, (8):1231-1233 2000
MED: 11071509
Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
Nicoletti F, Di Marco R, Patti F, Zaccone P, L'Episcopo MR, Reggio E, Xiang M, Nicoletti A, Reggio A
Cytokine, (6):682-687 2000
MED: 10843745

Citations & impact

Impact metrics

Citations

Jump to Citations

Citations of article over time

Smart citations by scite.ai
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1177/1352458509104593

Supporting

Mentioning

Contrasting

Article citations

Respiratory functions, respiratory muscle strength and fatigue in patients with pediatric-onset multiple sclerosis: a comparative cross-sectional study.
Vural P, Akinci B, Guler S, Saltik S, Yazgan YZ
Acta Neurol Belg, 21 Aug 2024
Cited by: 0 articles | PMID: 39168946
In the Search for Biomarkers of Pulmonary Arterial Hypertension, Are Cytokines IL-2, IL-4, IL-6, IL-10, and IFN-Gamma the Right Indicators to Use?
Tomaszewski M, Mertowska P, Janczewska M, Styczeń A, Mertowski S, Jonas K, Grywalska E, Kopeć G
Int J Mol Sci, 24(18):13694, 05 Sep 2023
Cited by: 2 articles | PMID: 37761997 | PMCID: PMC10530884
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
IFNAR2 relevance in the clinical outcome of individuals with severe COVID-19.
Fricke-Galindo I, Martínez-Morales A, Chávez-Galán L, Ocaña-Guzmán R, Buendía-Roldán I, Pérez-Rubio G, Hernández-Zenteno RJ, Verónica-Aguilar A, Alarcón-Dionet A, Aguilar-Duran H, Gutiérrez-Pérez IA, Zaragoza-García O, Alanis-Ponce J, Camarena A, Bautista-Becerril B, Nava-Quiroz KJ, Mejía M, Guzmán-Guzmán IP, Falfán-Valencia R
Front Immunol, 13:949413, 29 Jul 2022
Cited by: 19 articles | PMID: 35967349 | PMCID: PMC9374460
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Upregulation of IRF9 Contributes to Pulmonary Artery Smooth Muscle Cell Proliferation During Pulmonary Arterial Hypertension.
Chen YJ, Li Y, Guo X, Huo B, Chen Y, He Y, Xiao R, Zhu XH, Jiang DS, Wei X
Front Pharmacol, 12:773235, 01 Dec 2021
Cited by: 7 articles | PMID: 34925032 | PMCID: PMC8672195
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Role of the Immune System Elements in Pulmonary Arterial Hypertension.
Tomaszewski M, Bębnowska D, Hrynkiewicz R, Dworzyński J, Niedźwiedzka-Rystwej P, Kopeć G, Grywalska E
J Clin Med, 10(16):3757, 23 Aug 2021
Cited by: 19 articles | PMID: 34442052 | PMCID: PMC8397145
Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

Go to all (27) article citations

Search life-sciences literature (45,104,206 articles, preprints and more)

Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report.

Affiliations

Authors

Abstract

Full text links

References

Multiple sclerosis: side effects of interferon beta therapy and their management.

Vascular events associated with alpha interferon therapy.

Pulmonary side effects of interferon-alpha therapy in patients with hematological malignancies.

Pulmonary artery hypertension during interferon-alpha therapy for chronic myelogenous leukemia.

Acute right ventricular heart failure in a patient with renal cell carcinoma after interferon therapy.

Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report.

Interferon-alpha elevates pulmonary blood pressure in sheep--the role of thromboxane cascade.

Inflammation in pulmonary arterial hypertension.

Acute effects of interferon beta-1a on plasma cytokine levels in patients with MS.

Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.

Citations & impact

Impact metrics

Citations of article over time

Smart citations by scite.ai
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1177/1352458509104593

Article citations

Respiratory functions, respiratory muscle strength and fatigue in patients with pediatric-onset multiple sclerosis: a comparative cross-sectional study.

In the Search for Biomarkers of Pulmonary Arterial Hypertension, Are Cytokines IL-2, IL-4, IL-6, IL-10, and IFN-Gamma the Right Indicators to Use?

IFNAR2 relevance in the clinical outcome of individuals with severe COVID-19.

Upregulation of IRF9 Contributes to Pulmonary Artery Smooth Muscle Cell Proliferation During Pulmonary Arterial Hypertension.

Role of the Immune System Elements in Pulmonary Arterial Hypertension.

Similar Articles

Sildenafil therapy for interferon-β-1a-induced pulmonary arterial hypertension: a case report.

Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.

Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.

Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling.

Partnerships & funding

Similar Articles

Sildenafil therapy for interferon-β-1a-induced pulmonary arterial hypertension: a case report.
Cardiology, 120(4):187-189, 01 Jan 2011

Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Rheumatology (Oxford), 49(3):490-500, 16 Dec 2009

Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
Eur Respir J, 29(3):469-475, 01 Nov 2006

Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling.
J Cardiovasc Pharmacol, 56(5):475-483, 01 Nov 2010

Search life-sciences literature (45,104,206 articles, preprints and more)

Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report.

Author information

Affiliations

Authors

Abstract

Full text links

References

Citations & impact

Impact metrics

Citations of article over time

Article citations

Similar Articles

Partnerships & funding